HOME > ARCHIVE
ARCHIVE
- Industry Appreciates Improvements Made by National Hospitals to Facilitate Clinical Trials
May 30, 2005
- Astellas Pharma: Sales of \862 Bil. in 1st Settlement
May 30, 2005
- R&D NEWS IN BRIEF
May 30, 2005
- Eisai: Aricept, Pariet Drive Growth in Sales, Profits
May 30, 2005
- MEDICAL DEVICE NEWS IN BRIEF
May 30, 2005
- Shionogi: Profits Up Despite Dip in Sales
May 30, 2005
- OTC NEWS IN BRIEF
May 30, 2005
- Dainippon: Stronger Focus Boosts Operating, Ordinary Profits
May 30, 2005
- SURVEY 3 articles
May 30, 2005
- Ono: Major Products Bolster Growth in Sales, Profits
May 30, 2005
- Sales Up 0.3%, Net Profits Down 3.1% for Top Domestic Pharma Companies
May 30, 2005
- Kissei: Sales Rise 4.6% to \60,933 Bil.
May 30, 2005
- Santen: Domestic Market Spurs Growth in Sales
May 23, 2005
- PMDA Expediting the Review Process
May 23, 2005
- Kaken: Sales Up 3% to \74,922 Mil.
May 23, 2005
- Chuikyo Recommends Approval of Shionogi's Doripenem
May 23, 2005
- Taisho: Self-medication Sales Down 2.5% to \183,416 Mil.
May 23, 2005
- Central, Local Gov't Must Cooperate Closely to Effectively Implement Amended PAL
May 23, 2005
- Kyorin: Sales Up 1.9% to \66,296 Mil.
May 23, 2005
- Approval Standards Established for 3 Dietary Fibers, 6 Oligosaccharides
May 23, 2005
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
